Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:56:20 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:OLMA from 2023-05-18 to 2024-05-17 - 36 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-15 07:01U:OLMANews ReleaseOlema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
2024-05-08 16:02U:OLMANews ReleaseOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-08 07:02U:OLMANews ReleaseOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
2024-05-02 16:37U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-01 07:02U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences in May
2024-04-08 16:30U:OLMANews ReleaseOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
2024-04-02 16:29U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-11 16:03U:OLMANews ReleaseOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
2024-03-06 07:03U:OLMANews ReleaseOlema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
2024-03-04 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-06 07:01U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences
2024-02-02 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:13U:OLMANews ReleaseOlema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
2024-01-02 16:01U:OLMANews ReleaseOlema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 12:28U:OLMANews ReleaseOlema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
2023-12-04 16:29U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-28 17:10U:OLMANews ReleaseOlema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
2023-11-07 16:02U:OLMANews ReleaseOlema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-02 16:32U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-01 16:27U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences in November
2023-10-22 02:55U:OLMANews ReleaseOlema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
2023-10-17 07:01U:OLMANews ReleaseOlema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
2023-10-16 07:02U:OLMANews ReleaseOlema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
2023-10-12 07:01U:OLMANews ReleaseOlema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
2023-10-10 07:00U:OLMANews ReleaseOlema Oncology Announces Expansion of Collaboration Agreement with Novartis
2023-10-03 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-20 07:29U:OLMANews ReleaseOlema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-09-06 16:31U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences
2023-09-05 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 07:31U:OLMANews ReleaseOlema Oncology Announces Combined Financing for Up to $180 Million
2023-08-08 16:03U:OLMANews ReleaseOlema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-02 16:31U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-01 08:00U:OLMANews ReleaseOlema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-05 07:31U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-02 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-30 16:31U:OLMANews ReleaseOlema Oncology to Present at the 2023 Jefferies Healthcare Conference